Tirzepatide Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous Frequency: Once weekly Dose Range: 2.5–15 mg/week, titrated every 4 weeks Cycle Length: 12–16+ weeks; ongoing for weight/glycemic management Timing: Same day each week, any time, with or without food
Reconstitution
Vial Size: 5mg Water Volume: 2mL Concentration: 2.5mg/mL
Titration Schedule
Weeks 1–4: 2.5 mg Weeks 5–8: 5 mg Weeks 9–12: 7.5 mg Weeks 13–16: 10 mg Weeks 17+ (optional): 12.5–15 mg
Timeline & Pharmacokinetics
Onset: 24–72 hours (appetite suppression) Peak Plasma: 8–72 hours post-injection Half-Life: ~5 days (120 hours) Steady State: 4–5 weeks of weekly dosing Time to Results: 4–8 weeks for appetite changes; 12–20 weeks for significant weight loss Washout: 3–5 weeks (5 half-lives)
Storage
Lyophilized: −20 °C (−4 °F) Reconstituted: 2–8 °C (35.6–46.4 °F); use within 28 days Shelf Life: 28 days
Injection Sites
Abdomen, Thighs, Upper arms
Safety & Contraindications
Safety: Common (5%+ in trials): abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, vomiting Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems FDA boxed warning for thyroid C-cell tumors (rodent data); call doctor for neck lump, swallowing difficulty, hoarseness, or shortness of breath
Contraindications: Personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN2); Type 1 diabetes (not approved for this indication)
Related Products
Tirzepatide 10mg
10mg
Related Research News
Is Tirzepatide Better Than Semaglutide for Weight Loss? Comparison
A comparison examines if Tirzepatide outperforms Semaglutide for weight loss. The two drugs are directly contrasted on this measure. This regulatory news covers the key question of superiority.
Daily Orforglipron Preserves Weight Loss After Semaglutide or Tirzepatide
Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide. The medication supports maintenance of weight reduced during prior use of these treatments. Its once-a-day schedule aids in sustaining results from semaglutide or tirzepatide therapy.
FDA Proposes Ban on Bulk Compounding of Semaglutide and Tirzepatide
The U.S. Food and Drug Administration has proposed a ban on bulk compounding of semaglutide and tirzepatide. This regulatory proposal names semaglutide and tirzepatide as the drugs subject to the ban. The action focuses on prohibiting bulk compounding for these two medications.